Biodesix, Inc. (BDSX)
After hours:
| Previous close | 1.2900 |
| Open | 1.2500 |
| Bid | 1.2400 x 100 |
| Ask | 1.3100 x 100 |
| Day's range | 1.2400 - 1.2900 |
| 52-week range | 1.0300 - 2.2100 |
| Volume | |
| Avg. volume | 141,377 |
| Market cap | 146.348M |
| Beta (5Y monthly) | 1.12 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.6400 |
| Earnings date | 08 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 3.50 |
Business WireBiodesix to Report First Quarter 2024 Financial Results on May 8, 2024
LOUISVILLE, Colo., April 24, 2024--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced today that it will release financial results for the first quarter ended March 31, 2024 after the close of trading on Wednesday, May 8. Biodesix’s management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.
Simply Wall St.The recent US$4.0m market cap decrease is likely to have disappointed insiders invested in Biodesix, Inc. (NASDAQ:BDSX)
Key Insights Significant insider control over Biodesix implies vested interests in company growth 53% of the business...
Business WireBiodesix to Present New Data on Liquid Biopsy Technologies at AACR 2024 Annual Meeting
LOUISVILLE, Colo., April 09, 2024--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced that new data was presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, California. These presentations highlight advancements in liquid biopsy technologies that detect cell free DNA (cfDNA) and the clinical value of rapid turnaround time to detect actionable tumor mutations in a real-world clinical set
